OP2 Drugs SAS

📍 Pessac, France🗓 Founded 2015👥 4 employees
Pharmaceutical Manufacturing🌐 op2drugs.com
Website LinkedIn
OP2 Drugs SAS ("OP2"​) is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational. Based on strategic partnerships in Europe and in the US, we are generatling growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 Drugs is planned to move forward to clinic in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Michel Andraud (CFO), and funded by ambitious financial players.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was OP2 Drugs SAS founded?
OP2 Drugs SAS was founded in 2015.
What industry is OP2 Drugs SAS in?
OP2 Drugs SAS operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is OP2 Drugs SAS based?
OP2 Drugs SAS is headquartered in Pessac, France.